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Purpose—Discovery of single nucleotide polymorphisms (SNPs) that predict a patient's risk of 
docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and 
avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with 
docetaxel-induced neuropathy and mechanistically validate these associations in preclinical 
models of drug-induced neuropathy.
Experimental Design—A genome-wide association study was conducted in metastatic castrate-
resistant prostate cancer patients treated with docetaxel, prednisone and randomized to 
bevacizumab or placebo on CALGB 90401. SNPs were genotyped on the Illumina 
HumanHap610-Quad platform followed by rigorous quality control. The inference was conducted 
on the cumulative dose at occurrence of grade 3+ sensory neuropathy using a cause-specific 
hazard model that accounted for early treatment discontinuation. Genes with SNPs significantly 
associated with neuropathy were knocked down in cellular and mouse models of drug-induced 
neuropathy.
Results—498,081 SNPs were analyzed in 623 Caucasian patients, 50 (8%) of whom experienced 
grade 3+ neuropathy. The 1000 SNPs most associated with neuropathy clustered in relevant 
pathways including neuropathic pain and axonal guidance. A SNP in VAC14 (rs875858) surpassed 
genome-wide significance (p=2.12×10-8 adjusted p=5.88×10-7). siRNA knockdown of VAC14 in 
stem cell derived peripheral neuronal cells increased docetaxel sensitivity as measured by 
decreased neurite processes (p=0.0015) and branches (p<0.0001). Prior to docetaxel treatment 
VAC14 heterozygous mice had greater nociceptive sensitivity than wild-type litter mate controls 
(p=0.001).
Conclusions—VAC14 should be prioritized for further validation of its potential role as a 
predictor of docetaxel-induced neuropathy and biomarker for treatment individualization.
Keywords
docetaxel; paclitaxel; pharmacogenetics; genome-wide association study; heritability; single 
nucleotide polymorphism; chemotherapy-induced peripheral neuropathy; VAC14; peripheral 
neuronal cell model; animal model
Introduction
The taxane class includes three US Food and Drug Administration (FDA)-approved 
chemotherapeutic agents, paclitaxel, docetaxel and cabazitaxel, that have activity in a variety 
of solid tumors including lung, breast, ovarian, gastric, and prostate cancers. Taxanes bind to 
and stabilize microtubules, ultimately inhibiting the mitotic phase of cell cycle 
development(1). The taxanes and other microtubule-targeting chemotherapeutic agents (e.g., 
vinca alkaloids) commonly induce peripheral neuropathy of varying severity(2). 
Chemotherapy-induced peripheral neuropathy (CIPN) often presents as a combination of 
paresthesia and dysesthesia, and can progress to irreversible loss of balance and dexterity 
with continued treatment(3). Due to the progressive nature of the toxicity and its potential 
effect on long-term quality of life(4), CIPN can necessitate treatment discontinuation, even 
in the context of active tumor control.
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Patient demographic (i.e., race and history of neuropathy) and treatment (i.e., cumulative 
dose and drug exposure) factors have been associated with CIPN(5-8), but there are 
currently no effective methods for predicting CIPN risk and/or severity. Genome-wide 
association studies (GWAS) of paclitaxel and vincristine-induced CIPN confirm that genetic 
variation modifies patients' risk(9-12). The discovery and validation of single nucleotide 
polymorphisms (SNPs) that influence risk of docetaxel-induced peripheral neuropathy 
would be of clinical benefit, enabling identification of high-risk patients in whom taxane use 
should be avoided if possible. SNPs that modulate risk of docetaxel-induced neuropathy 
have been reported from candidate gene studies(13-15); however, no study has taken a 
genome-wide approach. Based on the previous success of GWAS in discovering SNPs that 
affect paclitaxel-induced neuropathy, a similar analysis was conducted in a cohort of 
docetaxel-treated patients to identify genetic predictors of docetaxel-induced neuropathy.
GWAS was performed in a large, prospectively enrolled, chemotherapy-naive cohort of 
metastatic castrate-resistant prostate cancer (mCRPC) patients who were treated with up to 
two years of docetaxel and prednisone, with half randomized to concurrent 
bevacizumab(16). As these metastatic patients are at high risk of early treatment 
discontinuation due to disease progression and/or death, which precludes occurrence of 
neuropathy, a competing-risks adjusted statistical model was utilized(17, 18). Following 
discovery of a SNP that surpassed genome-wide significance, pharmacogenetic replication 
between the results of a previously conducted GWAS of paclitaxel-induced neuropathy(9) 
and this GWAS of docetaxel-induced neuropathy and mechanistic validation of that gene in 
cellular and animal models were attempted to determine whether genetic predictors of CIPN 
were similar between the taxanes and to potentially validate clinically useful genetic 
predictors of docetaxel-induced sensory peripheral neuropathy
Methods
Patients and toxicity
Cancer and Leukeumia Group B (CALGB/Alliance) 90401 was a double-blinded phase III 
trial that equally randomized men with hormone-refractory prostate cancer to receive 
docetaxel and prednisone with or without bevacizumab for up to two years(16). All patients 
enrolled in the CALGB 90401 parent study who provided IRB-approved informed consent 
for a pharmacogenomic substudy (CALGB 60404) were eligible for this GWAS. Briefly, 
patient eligibility included histologically documented adenocarcinoma of the prostate that 
had progressed while the patient was on hormone deprivation therapy. Relevant exclusion 
criteria included prior chemotherapy or anti-angiogenesis therapy or clinically significant 
(grade 2+) peripheral neuropathy. Toxicity data were collected by the Alliance Statistics and 
Data Center at each treatment cycle on standardized forms that mandated reporting of grade 
3+ peripheral sensory neuropathy, as defined by National Cancer Institute Common Toxicity 
Criteria for Adverse Events (NCI CTCAE) version 3.0. Additionally, one case was reported 
as a grade 3 cranial neuropathy event described as “sensory-facial.” Only neuropathy that 
was considered by the clinician to be possibly, probably, or definitely attributable to 
treatment, and occurred within 30 days of docetaxel administration, was included in the 
analysis.
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Docetaxel treatment
All patients received docetaxel 75 mg/m2 infused over 1 hour on day 1 of each 21-day cycle 
with 8 mg oral dexamethasone 12, 3, and 1 hour prior to infusion. Patients on both arms also 
received 5 mg oral prednisone twice daily and were randomized to 15 mg/kg bevacizumab 
or placebo by intravenous infusion on day 1 of each cycle. Use of growth factor, aspirin, 
anti-emetics and luteinizing-hormone releasing hormone agonists was under the discretion 
of the treating physician. Docetaxel administration was held for neutropenia (absolute 
neutrophil count <1,500 cells/mm3) and the dose was decreased in increments of 10 mg/m2 
for hepatic dysfunction, neurotoxicity, gastrointestinal toxicity or febrile neutropenia. The 
protocol mandated discontinuation of docetaxel treatment if the patient required more than 
two docetaxel dose decreases or in the event of specific toxicities or confirmed cancer 
progression.
Genotyping
A 10-mL sample of whole blood was collected from all patients enrolling on the 
pharmacogenomic substudy prior to initiation of protocol treatment. Genotyping and genetic 
quality control were similar to that previously reported in the CALGB 40101 GWAS(9). 
Genotyping was performed on the HumanHap610-Quad Genotyping BeadChip (Illumina 
Inc., CA, USA) at the RIKEN Center for Genomic Medicine (Yokohama City, Japan). 
Genotype data is available at dbGap (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs001002.v1.p1) SNPs that were known indeterminate (n=4,106) or 
unreliable loci (Tech Note: Infinium® Genotyping Data Analysis, 2007) and patients with 
SNP call rate <95% were excluded. Eigensoft version 3.0 was used to visualize genetic 
ancestry for the 790 evaluable patients to identify a genetic European population (n=623) in 
which the analysis was conducted. Additional SNPs were excluded for low call rate (<99%), 
low minor allele frequency (<0.05), p-value of Hardy-Weinberg distribution <10-8 or non-
autosomal loci, leaving 498,081 SNPs for analysis (Supplementary Figure 1).
Cellular Sensitivity Experiments
Commercially available human induced pluripotent stem cell (iPSC)-derived peripheral 
neurons (Peri.4U) were purchased from Axiogenesis (Cologne, Germany) and plated at 1 × 
104 cells/well in 100 μL media as per manufactures' instructions. Figure 3A illustrates the 
scheme for this experiment. Dharmacon Accell technology (GE Dharmacon, Lafayette, CO, 
USA) was applied at 4 hours post-plating using 1 μM human siVAC14 SMARTpool or the 
non-targeting control (NTC). 24 hours later, transfection media was exchanged for media 
containing 0.17% DMSO vehicle control and either docetaxel (LKT Laboratories Inc., St. 
Paul, MN) or paclitaxel (Sigma-Aldrich, St. Louis, MO). The drugs were prepared in a 
darkened hood by dissolving powder in 100% DMSO to obtain a stock solution of 58.4 mM. 
Stock drug was serially diluted in media for final dosing concentrations ranging from 10 pM 
to 1 μM, increasing by factors of ten. Control wells were treated with 0.17% final 
concentration of DMSO to match drug treatments. After 24 or 48 hour drug treatments, 
neurons were stained with 0.3 ng/mL Hoechst 33342 (Sigma-Aldrich) and 1.5 μg/mL 
Calcein AM (Molecular Probes, Life Technologies Inc.) and imaged at 10× magnification 
using an ImageXpress Micro imaging microscope (Molecular Devices, LLC, Sunnyvale, 
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CA) at the University of Chicago Cellular Screening Center. Neurite changes were 
determined by individual cell measurements of relative total neurite outgrowth, relative 
number of processes, relative number of branches, mean/median/max process length, 
relative cell body area, relative straightness and relative mean outgrowth intensity. The data 
represents triplicate experiments making measurements on more than 1000 cells per 
treatment as previously described(19). Two wells of transfected cells were collected per 
timepoint using the Cells-to-Ct kit (Ambion, Life Technologies Inc., Carlsbad, CA) and 
reversed transcribed as per kit instructions. Quantitative real time reverse transcription 
polymerase chain reaction (qRT-PCR) was performed using Taqman primers (Fisher 
Scientific LLC, Hanover Park, IL) for VAC14 (Hs00947931_m1) and compared to human 
beta-2-microglobulin (NM_004048.2) housekeeping gene at 24, 48 and 72 hours post-
transfection (as previously described; (19).
Mouse Sensitivity Experiments
Mice bred for VAC14 heterozygosity (VAC14+/-) and VAC14 wild-type litter mates 
(VAC14+/+) on C57/BL6 background were obtained from Lois Weisman at University of 
Michigan and acclimated to living conditions at University of Maryland(20). Mice 3-5 
months of age were randomly assigned to docetaxel or placebo treatment, with 6-7 mice in 
each treatment arm. The entire experiment was conducted separately in male and female 
mice. Intraperitoneal administration of docetaxel 2 mg/kg or saline vehicle was administered 
on days 1, 3, 5, and 7.
Behavioral testing for the development of increased mechanical sensitivity took place at 
baseline (prior to treatment), day 5 (after two doses), day 8 (24 hours after the fourth dose), 
and weekly for 3 additional assessments. Mechanical sensitivity was measured in mice from 
both treatment arms simultaneously by a blinded individual using von Frey filaments, as 
previously described(21). Briefly, mice were placed in individual Plexiglas® cubes on an 
elevated wire mesh platform and allowed to acclimate for approximately one hour, when 
grooming and exploration behaviors ended. A series of von Frey filaments (Touch Test 
Sensory Evaluator Kit, myNeurolab.com, St. Louis, MO), with bending forces of 0.04-2.0 g, 
were applied to the plantar surface of the left hind paw until the filament just bent and was 
held in place for 5 seconds or until the mouse withdrew its paw. A positive response was 
defined as a brisk withdrawal, with or without shaking or licking, of the hind paw during or 
immediately upon removal of the filament application. Each filament was tested 5 times on 
each hind paw starting with the 0.4 g filament. If the 0.4 g filament elicited 3 positive 
responses out of 5 trials, then testing continued moving downward through the series to the 
0.04 g filament and the number of withdrawals was recorded for each filament. If the 0.4 g 
filament did not elicit 3 positive responses, then testing continued moving upward through 
the series to the 2.0 g filament and the number of withdrawals was recorded for each 
filament. Threshold was defined as the filament with the lowest bending force that elicited at 
least 3 positive responses out of 5 trials.
Statistics
The primary endpoint for GWAS analysis was the cumulative docetaxel dose (mg/m2) at 
first report of treatment-related grade 3+ sensory peripheral neuropathy. Patients who did not 
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complete two years of therapy due to progression/death, treatment-terminating adverse 
event, or any other reason were informatively censored at the cumulative docetaxel dose 
received; therefore, the statistical analysis was conducted within a competing-risk model 
framework with the inference conducted on the basis of cause-specific hazard(17, 18). 
Cumulative incidence curves were constructed to visualize the influence of each of the top 
three hits with neuropathy incidence. The relationship between each SNP and neuropathy 
was adjusted for clinical covariates with putative relevance to neuropathy risk: diabetes 
(reported history of diabetes or current diabetes treatment vs. none), age (continuous), body 
mass index (BMI) (≤ 30 kg/m2 vs. > 30 kg/m2), and treatment arm (bevacizumab vs. 
placebo), regardless of whether the covariate was significantly associated with neuropathy in 
this cohort.
Cross-study clinical replication of the SNP with the greatest association with neuropathy 
was attempted in a cohort of Caucasian breast cancer patients treated with paclitaxel on the 
CALGB 40101 clinical trial(22). GWAS of the cumulative paclitaxel dose at occurrence of 
grade 2+ neuropathy has previously been published(9). Additionally, a SNP predictive of 
paclitaxel-induced neuropathy risk (rs10771973, FGD4) discovered and replicated in the 
CALGB 40101 GWAS was interrogated in the GWAS results from the docetaxel-treated 
Caucasian patients on CALGB 90401 to assess whether the SNPs that influence neuropathy 
risk are similar between the two taxanes.
Statistical analyses were performed by Alliance statisticians on a database locked on August 
15, 2012. All analyses were conducted using the R [R]statistical environment version 
3.1.1(23) or higher, using extension packages survival (version 2.37-7)(24), GenABEL 
(version 1.8-0)(25), cmprsk (version 2.2-7)(26) and interval (version 1.1-0.1)(27). To search 
for cumulative genetic effects, the genes that mapped to the top 1000 SNPs were included in 
a pathway enrichment analysis using the Ingenuity Pathway Analysis version 17199142 
(Ingenuity® Systems, Inc, www.ingenuity.com) internal algorithm. Peripheral neuronal cell 
phenotypes (outgrowth, processes, branching, etc.) measured after treatment with increasing 
docetaxel and paclitaxel concentrations were compared between VAC14 siRNA and non-
targeted control siRNA using two-way ANOVA.
Mouse mechanical sensitivity thresholds were compared prior to docetaxel treatment 
between VAC14+/+ and VAC14+/- mice using an interval-censored analysis with the 
minimum fiber size inducing a response as the phenotype. The genotype groups in the 
untreated mice were compared again on day 28. The same method was used to compare 
sensitivity thresholds of docetaxel treated and untreated mice following treatment on day 8. 
To assess whether VAC14+/- mice were more sensitive to docetaxel-induced changes in 
mechanical stimuli, parametric survival regression was used to test for the effect of VAC14 
by treatment interaction on withdrawal threshold on day 8, after treatment was completed.
Results
Genome-wide Association Study
The CALGB/Alliance 90401 parent study enrolled 1,050 patients, of whom 863 provided 
consent and registered for the pharmacogenomics substudy CALGB 60604 (CALGB is now 
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a part of the Alliance for Clinical Trials in Oncology). The GWAS included 790 patients, of 
whom only the 616 self-reported, genetically defined Europeans receiving treatment were 
included in the analysis to minimize confounding from population substructure 
(Supplementary Figure 1). Demographic characteristics for the discovery cohort including 
baseline covariates potentially relevant to treatment-induced neuropathy risk are reported in 
Table 1. The median age was 69 years, body mass index (BMI) was 29 kg/m2, and 97 
patients (16%) had a history of diabetes. Randomization was nearly even to the bevacizumab 
(314 patients, 51%) and placebo (302, 49%) arms.
The overall incidence of grade 3+ sensory neuropathy was 8.1% (50/616). The 566 patients 
who did not experience neuropathy were classified as having either completed treatment 
without neuropathy (3.9%) or categorized based on their reason for discontinuation: death/
progression (41.1%), non-CIPN treatment terminating adverse event (30.2%) or withdrawal/
other (16.7%) (Supplementary Table 1). The risk of neuropathy was not significantly 
different in the bevacizumab and placebo arms (p=0.11), which were pooled for analysis.
GWAS analysis was performed on the cumulative docetaxel dose (mg/m2) at first report of 
treatment-induced grade 3+ sensory peripheral neuropathy (Figure 1). The ten most 
significant SNPs, ranked according to the unadjusted p-value for cause-specific association 
with neuropathy, are listed in Table 2 with rsID, gene annotation, and hazard ratios before 
and after adjustment (Top 1000 SNPs in Supplementary Table 2). One SNP surpassed 
Bonferonni-corrected significance (0.05/498,022=1.004×10-7). This is an intronic SNP in 
the VAC14 gene (rs875858, minor allele frequency=0.056), which increased neuropathy risk 
(HR=3.60, 95%CI: 2.21-5.84, p=2.12×10-8, Figure 2A). The second and third most strongly 
associated SNPs were an intergenic SNP (rs11017056, MAF=0.223, HR=2.61, 95%CI: 
1.77-3.84, p=3.84×10-7) and an intronic SNP in the ATP8A2 gene (rs1326116, MAF=0.194, 
HR=2.77, 95%CI: 1.79-4.27, p=1.77×10-6), both of which increased neuropathy risk 
(Figures 2B and 2C).
The associations of all SNPs were then adjusted for treatment arm and several clinical 
covariates previously reported to be relevant to neuropathy risk including diabetes, age, and 
BMI. In this particular cohort, among the clinical covariates only increasing age (p=0.0003) 
was significantly associated with neuropathy, though increasing BMI showed a trend toward 
association (p=0.05). Covariate adjustment did not substantially affect the results, though the 
association of VAC14 fell below the Bonferonni-corrected significance threshold after 
adjustment (p=5.88 ×10-7). The top 1000 SNPs mapped to 240 unique genes, which were 
included in the pathway analysis. The three most significantly enriched pathways in the 
GWAS are displayed in Supplementary Table 3. Notably, two of these enriched pathways are 
relevant to CIPN; Axonal Guidance (p=1.20×10-4) and Neuropathic Pain Signaling in Dorsal 
Horn Neurons (p=6.03×10-3).
Cross-GWAS Pharmacogenetic Replication
Due to the absence of a large cohort of docetaxel-treated patients with prostate cancer in 
which to perform replication, and our interest in assessing whether taxanes share genetic 
predictors of neuropathy risk, cross-study pharmacogenetic replication was attempted in a 
cohort of paclitaxel-treated Caucasian patients with breast cancer enrolled on CALGB 
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(Alliance 40101). The VAC14 SNP (rs875858) discovered in our docetaxel-induced 
neuropathy GWAS was not associated with paclitaxel-induced neuropathy in the 40101 
study (p=0.70)(9). In addition, SNPs that were discovered in previously published GWAS of 
paclitaxel-induced neuropathy (FGD4 (rs10771973) p=0.39, EPHA4 (rs17348202) p=0.76, 
EPHA5 (rs7349683) p=0.15, intergenic (rs3125923) p=0.057, FCAMR (rs1856746) p=0.25) 
(9, 10, 12) or candidate SNP studies of docetaxel-induced neuropathy (GSTP1 Ala114Val 
(rs1138272) p=0.98, ABCB1 1236C>T (rs1128503) p=0.62, ABCB1 (rs4148738) p=0.90, 
ABCB1 3435C>T (rs1045642) p=0.80) (13-15) were not associated with docetaxel-induced 
neuropathy occurrence in the CALGB 90401 patients. Finally, when comparing the top 
SNPs from taxane-induced neuropathy GWAS performed within CALGB 90401 (docetaxel) 
and 40101 (paclitaxel), there was no statistical evidence that the degree of overlap was 
greater than would be expected by random chance (data not shown).
Peripheral Neuronal Cell Sensitivity
To determine the effect of VAC14 knockdown on neuronal sensitivity to docetaxel and 
paclitaxel, commercially available human iPSC-derived peripheral neurons (Peri4.U) were 
utilized. At the time of image analysis, which is 24 and 48 hours post drug treatment (48 and 
72 h post transfection), expression of VAC14 in neurons treated with 1 μM siRNA had 
decreased to 54 and 44%, respectively, as compared to control cells treated with a non-
targeting siRNA (Figure 3B). The VAC14 siRNA knockdown at 24 hours post-docetaxel 
treatment did not affect relative total outgrowth (Figure 3C) in the peripheral neurons but 
resulted in significantly greater sensitivity to docetaxel as measured by relative number of 
processes (p=0.0015, Figure 3D) and relative number of branches (p<0.0001, Figure 3E) 
Similar effects were found in preliminary studies of VAC14 knockdown in a human IPSC-
derived cortical neuron, iCell® Neurons measured 48 hours after treatment (Cellular 
Dynamics International, Madison, WI) (data not shown). In contrast, VAC14 siRNA 
knockdown significantly decreased peripheral neuronal cell sensitivity to paclitaxel as 
measured by these same cellular phenotypes (all p<0.05, Figure 3F-3H). Other 
morphological characteristics including mean process length, mean outgrowth intensity and 
relative straightness were also measured for docetaxel and paclitaxel (Supplementary Figure 
2). We found a decreased sensitivity to docetaxel and paclitaxel when measuring mean 
process length and for mean outgrowth intensity for paclitaxel only. There was no difference 
in measurements of relative straightness (data not shown).
Mouse Mechanical Sensitivity
Prior to receiving docetaxel treatment, VAC14+/- heterozygous mice were more sensitive 
than wild type VAC14+/+ mice to mechanical stimuli using von Frey filaments (p=0.001, 
Supplementary Figure 3). When stratified by gender this effect was significant in male mice 
(p=0.002) but not female mice (p=0.16), however, there was no statistically significant 
gender interaction (p=0.10). The difference in sensitivity to mechanical stimuli between 
genotype groups at baseline was attenuated over the course of the experiment in untreated 
mice, as there was no evidence of a difference between these groups from at the end of the 
experiment (p=0.23). As expected, 8 days of docetaxel treatment increased sensitivity to 
mechanical stimuli compared to untreated control mice, regardless of mouse genotype 
(p<0.0001, Figure 4). Comparing across genotype groups, there was no difference between 
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VAC14+/- and VAC14+/+ mice in docetaxel-induced increase in threshold sensitivity to 
mechanical stimuli at day 8 (p=0.18) or day 14 (p=0.80) when the neuropathy was at its 
maximum.
Discussion
GWAS in a large cohort of mCRPC patients receiving docetaxel treatment identified an 
intronic SNP (rs875858) within VAC14 that was associated with increase neuropathy risk 
(HR=3.60). VAC14 has been directly linked to neurodegeneration in animal models(20) and 
linked to hereditary neuropathy conditions in humans(28). The lack of clinical replication in 
a cohort of paclitaxel-treated breast cancer patients is perhaps due to known differences 
between the two taxanes, including neuropathy profile(29). Distinct genetic modifiers of 
cellular sensitivity to paclitaxel and docetaxel have been previously reported in in vitro 
models(30) and the results of cellular sensitivity experiments demonstrating that VAC14 
knockdown enhances sensitivity of peripheral neurons to docetaxel but not paclitaxel for 
relative number of processes and relative branching, further support this hypothesis. Given 
the distinct genetic effects on neuronal sensitivity to docetaxel and paclitaxel it is 
conceivable that the polymorphisms that affect neuropathy risk also differ between the two 
taxanes. This would be consistent with the lack of cross-study replication, including the lack 
of association with docetaxel-induced neuropathy occurrence in this analysis for SNPs 
(FGD4, EPHA4 and EPHA5) that have been previously discovered, and in some cases 
replicated, in paclitaxel-induced neuropathy GWAS (9, 10, 12, 31). Alternatively, 
heterogeneity between the patient cohorts, including differences in gender, age, and 
functional status, or differences in the phenotype (grade 2+ vs. grade 3+), may explain the 
lack of replication across the clinical GWAS. This GWAS was also not able to replicate 
previously reported associations between docetaxel-induced neuropathy and SNPs in 
ABCB1(15) or GSTP1(13, 14) reported in previous candidate SNP studies, similar to the 
failure of paclitaxel GWAS to replicate associations with candidate SNPs including 
CYP2C8*3(32).
The mechanistic importance of VAC14 in docetaxel-induced neuropathy was tested in two 
pre-clinical models of CIPN. Knockdown of VAC14 in the peripheral neuronal cell model 
(Peri.4U) increased sensitivity to docetaxel treatment as measured by decreased neurite 
number of processes and neurite branching. Interestingly, knockdown of VAC14 seemed to 
decrease cellular sensitivity to paclitaxel treatment for these morphological characteristics 
suggesting that this gene may play an important role in the damage to processes and 
branching induced by docetaxel but not paclitaxel. A similar model of human neuronal cell 
sensitivity that utilizes induced pluripotent cortical neurons (iCell® Neurons) has previously 
been used for mechanistic validation of GWAS hits that increases risk of paclitaxel-induced 
neuropathy(19, 33) and vincristine-induced neuropathy(11). These human model systems 
have several advantages over the use of rodent cell lines such as rat pheochromocytoma cell 
lines, PC12 or NS1. One major limitation of rodent cell lines is the required treatment with 
nerve growth factor to initiate nerve outgrowth, which confounds the evaluation of drug 
treatment effects(34-36).
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To our knowledge this is the first study to attempt mechanistic validation of a finding from a 
clinical GWAS in an animal model of CIPN. The Von Frey Filament Test is a well-
established rodent model to test sensitivity to nociceptive stimuli, as a surrogate for 
peripheral neuropathy, that is commonly used for mechanistic investigation of 
neuropathy(21, 37, 38). Unlike the cell experiment, VAC14 heterozygous mice were not 
more sensitive than wild-type littermates to the effect of docetaxel, but were more sensitive 
to mechanical stimuli prior to treatment. The enhanced sensitivity in the heterozygous mice 
at baseline was attenuated over time in the untreated cohort, in both male and female mice. It 
is possible that these mice acclimate to the discomfort of the mechanical stimuli or they may 
be experiencing numbness, another characteristic symptom of peripheral neuropathy in 
taxane-treated patients, though additional experiments would be required to test either 
hypothesis. It is unclear from these findings whether patients with VAC14 polymorphisms 
have subclinical neuropathy at baseline that is expressed by treatment, as suggested by the 
mouse data, or whether they are similar at baseline and have greater neuropathy 
development from docetaxel treatment. Subjective testing that is sensitive for subclinical 
neuropathy, perhaps with electrophysiological or quantitative sensory assessment(39), in 
untreated patients with wild-type and polymorphic VAC14 may help resolve this 
conundrum.
The VAC14 protein provides a scaffold for the lipid kinase PIKfyve and its positive 
regulator, FIG4. These proteins reside in a complex that is responsible for the generation of 
the signaling lipids phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2) and PI5P. These 
lipids are essential in multiple tissues(28). The inability of VAC14-/- homozygous mice to 
survive beyond 1-2 days after birth necessitated the use of VAC14+/- heterozygous mice(20). 
On autopsy AC14-/- homozygous mice exhibit massive neurodegeneration with cell bodies 
in the central and peripheral nervous system containing large vacuoles. This 
neurodegeneration and vacuolization are similar to that found in FIG4 null mice, suggesting 
that variation in these genes is likely to phenocopy in humans as well as in mice(40). A rare 
mutation in the FIG4 gene is known to cause a subtype of Charcot-Marie-Tooth disease, a 
hereditary neuropathy syndrome(41). Interestingly, the CALGB 40101 paclitaxel-induced 
neuropathy GWAS discovered and replicated an association for a SNP in FGD4 
(rs10771973), another gene known to cause Charcot-Marie-Tooth disease(42), though this 
variant was not associated with docetaxel-induced neuropathy in our CALGB 90401 cohort.
The SNP (rs875858) discovered in this GWAS lies within an intron of the VAC14 gene. It is 
unclear what effect, if any, this individual SNP has on VAC14 expression or activity in the 
peripheral neuron. In the GTEx database there is no association between rs875858 and 
VAC14 gene expression in the tibial nerve tissue, though the power of this analysis is limited 
by the relatively small number of samples (n=256) and low minor allele frequency 
(MAF=0.06) of this SNP http://www.gtexportal.org/home/eqtls/bySnp?
snpId=rs875858&tissueName=Nerve_Tibial. In the larger DGN cohort (n=922), rs875858 is 
highly associated with IL34 (p=4e-7) expression in whole blood. IL-34 is structurally similar 
to colony-stimulating factor 1 and both are ligands of the colony-stimulating factor 1 
receptor(43), which has recently been identified as an efficacious target in mouse models of 
Charcot-Marie-Tooth disease(44), providing an alternative plausible biological mechanism 
for this association. Finally, it is conceivable that this SNP is not functionally relevant but 
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instead is a genetic marker of a different causative SNP; however, rs875858 lies in a region 
of low linkage disequilibrium.
The SNP (rs1326116) with the third strongest association with docetaxel-induced 
neuropathy is an intronic polymorphism in the ATP8A2 gene, which encodes ATP8A2, a P4 
ATPase. The P-type ATPases are a superfamily of proteins that translocate phospholipids 
between the two leaflets of cellular lipid bilayers(45). Several lines of evidence link ATP8A2 
to neurological development and function; in vitro data that ATP8A2 overexpression 
enhances neurite outgrowth(46), animal data that ATP8A2 mutations cause overt progressive 
neurodegeneration in Wabbler-lethal mice by disrupting axonal transport and polarity(47), 
and case reports of ATP8A2 mutations causing severe neurological phenotypes in 
patients(48, 49).
The three pathways most highly enriched in the GWAS results include axonal guidance and 
neuropathic pain signaling, both of which have obvious relevance to taxane-induced 
peripheral neuropathy. Growth and maintenance of neuronal axons requires organization of 
microtubules into a cytoskeleton(50). Taxanes stabilize microtubules, potentially interfering 
with cytoskeletal organization leading to the overt neuropathic symptoms reported by 
patients. Enrichment in a similar pathway, axonal outgrowth, was reported in a secondary 
analysis of a paclitaxel-induced neuropathy GWAS, suggesting that these two studies are 
identifying similar genetic signatures(51), despite the lack of overlap of individual SNPs in 
the top 1000 hits. Neuropathic pain is one of the characteristic clinical manifestations of 
taxane-induced neuropathy, in addition to sensory and motor components(2). Neuropathic 
pain signaling in the dorsal horn neurons may contribute to taxane-induced peripheral 
neuropathy via a higher propensity for development of central sensitization(52).
The primary limitation of this study is the lack of availability of an independent clinical trial 
cohort of docetaxel-treated patients for pharmacogenetic replication. Another limitation is 
the reliance on the protocol-specified collection of severe peripheral neuropathy (grade 3 or 
higher), rather than systematic collection across all toxicity grades. It is possible that some 
patients experienced grade 2 neuropathy without progressing to grade 3, and thus were not 
included as neuropathy events in this analysis. Furthermore, ordinal analysis across all 
neuropathy grades (0-4) would have brought greater statistical power and may have 
identified a distinct set of SNPs that predict neuropathy severity, similar to the paclitaxel-
induced neuropathy GWAS findings in CALGB (Alliance) 40101(9). The lack of grade 1 or 
2 neuropathy data collection may explain the absence of events in the patients homozygous 
for the rs875858 SNP. However, two of these patients discontinued docetaxel treatment quite 
early, after 6 (442 mg/m2) and 8 (561 mg/m2) cycles for progression and grade 3 nausea/
vomiting, respectively. The third patient was discontinued after 26 cycles (1,746 mg/m2) for 
a constellation of grade 3 toxicities including cough, dyspnea, fatigue, febrile neutropenia, 
and pneumonitis, without any documentation of peripheral neuropathy during treatment. The 
collection of DNA and comprehensive baseline and outcomes data, including accurate 
assessment of timing and severity of peripheral neuropathy, in other large clinical cohorts 
will allow for independent replication of our findings.
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In conclusion, GWAS of a prospectively enrolled patient cohort identified a SNP in VAC14 
that predicts sensitivity to docetaxel-induced peripheral neuropathy. VAC14 heterozygous 
mice were subsequently shown to be more sensitive to nociceptive stimuli at baseline, and 
peripheral neuronal cell (Peri.4U) sensitivity to docetaxel is enhanced after VAC14 
knockdown, providing mechanistic validation of the relevance of VAC14 to docetaxel-
induced neuropathy. However, the relatively low hazard ratio of this SNP suggests that no 
single variant or gene is responsible for dictating neuropathy sensitivity or will be clinically 
useful for personalizing docetaxel treatment. This is consistent with the multifactorial nature 
of neuropathy that depends on both drug exposure and a variety of patient factors, including 
age and BMI, which were associated with neuropathy occurrence in this cohort. Replication 
of the influence of our top candidate SNPs on neuropathy risk in a similar clinical trial 
cohort of docetaxel-treated mCRPC patients is of great interest to validate the role of these 
genes and provide support for further investigation into this mechanism for chemotherapy-
induced neuropathy prevention or treatment.
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Statement of Translational Relevance
The taxanes are a class of chemotherapeutic agents that are commonly associated with 
treatment-limiting peripheral sensory neuropathy. Genetic predictors of paclitaxel-
induced neuropathy have been discovered but little is known about whether similar 
genetic factors are associated with risk of docetaxel-induced neuropathy. Discovery of 
genetic predictors of docetaxel-induced neuropathy could inform personalized treatment 
decisions to maximize efficacy and avoid unnecessary toxicity. We conducted a genome-
wide association study in a large cohort of Caucasian men with hormone refractory 
prostate cancer treated with docetaxel. One single nucleotide polymorphism in VAC14 
that was significantly associated with docetaxel-induced neuropathy was then 
mechanistically validated in cellular and animal models of neurotoxicity. These finding 
suggest that distinct genetic variants influence risk of peripheral neuropathy from 
paclitaxel and docetaxel. The genetic variant identified in this study could be useful for 
understanding the mechanism of docetaxel-induced neuropathy and may be informative 
for avoiding docetaxel treatment in patients at elevated neuropathy risk.
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Figure 1. Genome-wide association results
Manhattan plot displaying the unadjusted p-value for the association of cumulative docetaxel 
dose at grade 3+ sensory neuropathy for all SNPs that passed quality control (n=498,022). 
One SNP (rs875858) surpassed the Bonferonni-corrected significance threshold of 1.0×10-7.
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Figure 2. Incidence of Neuropathy by Genotype for Highly Associated SNPs
Cumulative incidence curve of docetaxel dose at grade 3+ neuropathy occurrence stratified 
by genotype for the top three hits: A) a VAC14 intronic SNP (rs875858), B) an intergenic 
SNP (rs11017056), and C) an ATP8A2 intronic SNP (rs1326116). In each case, carrying the 
variant allele increased neuropathy risk compared to wild-type patients, though there were 
too few patients who were homozygous for the rare VAC14 variant (n=3) to draw 
meaningful conclusions in this group.
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Figure 3. VAC14 Knockdown increases neuronal cell sensitivity to docetaxel but decreases 
sensitivity to paclitaxel
A) Peripheral neuron (Peri.4U) experimental scheme illustrating timing of treatment and 
imaging. B) Relative VAC14 expression at 24, 48 and 72 hours post-transfection with 
siVAC14 compared to non-targeting control (NTC) produced a steady decline of VAC14 
expression over time. The neurite outgrowth changes after 24 hours docetaxel (48 hours 
knockdown) showed no significance as measured by C) total outgrowth but did result in 
greater sensitivity to docetaxel in D) relative number of processes and E) relative number of 
branches. Alternatively, VAC14 knockdown decreased peripheral neuronal cell sensitivity to 
paclitaxel, 3F-3H. Open circle represent data from VAC14 siRNA and closed circle from 
NTC siRNA. Neurite parameters measured with MetaXPress® software were averaged from 
3 independent experiments. Error bars represent the standard error of the mean from three 
independent transfection experiments. NTC = non-targeting control, UT= untransfected 
control.
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Figure 4. Docetaxel Treatment Increases Nociceptive Sensitivity in VAC14 Heterozygous and 
Wild-type Mice
The withdrawal threshold is defined as the lightest fiber weight that caused each mouse to 
withdraw their hind paw at least three times out of five. Each mouse has a withdrawal 
threshold at each time-point in the study. The mean withdrawal threshold is the average of 
12-14 mice (6-7 for each gender) for each treatment condition (VAC14 genotype and 
docetaxel treatment). Docetaxel- treated mice of either genotype had greater hindpaw 
withdrawal sensitivity following the end of treatment at day 8 compared to the untreated 
control mice (p<0.0001). There was no significant difference in the docetaxel-induced 
increase in withdrawal sensitivity comparing VAC14 heterozygous and wild-type mice 
(p=0.18).
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Table 1
Demographic Data for Patients Included in GWAS (n=616).
Age
Median (years) 68.9
Range (years) 41.7-93.5
Body mass index
Median (kg/m2) 29.0
Range (kg/m2) 16.1-53.3
Diabetes
Yes 97 (15.8%)
No 519 (84.3%)
Treatment arm
Bevacizumab 314 (51.0%)
Placebo 302 (49.0%)
Cumulative docetaxel dose
Median (mg/m2) 626
Range (mg/m2) 72-2,942
ECOG performance status
0 340 (55.2%)
1 258 (41.9%)
2 18 (2.9%)
Disease type Measurable disease 310 (50.3%)
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